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Acute kidney injury is an unfortunate complication of acyclovir therapy secondary to crystal-induced nephropathy. It is
characterized by a decrease in renal function that develops within 24–48 hours of acyclovir administration indicated by a rapid
rise in the serum creatinine. Failure to quickly realize this as an etiology of acute kidney injury can lead to excessive morbidity
to the patient. The case described in this vignette is an example of the clinical manifestation of acyclovir crystal obstructive
nephrotoxicity. We will brieﬂy discuss the pathophysiology, diagnosis, prevention, and management of patients that present with
acyclovir nephrotoxicity.
1.Introduction
Acute kidney injury is a well-described side eﬀect of
acyclovir, the most common mechanism being crystal
nephropathy. Unfortunately, although the side-eﬀects of
acyclovir are well known, they are often underappreciated.
Acute kidney injury secondary to acyclovir is characterized
by a decrease in renal function that usually develops within
12–48 hours of drug administration as indicated by a rapid
rise in the serum creatinine (S-Cr) [1]. Immediate detection
of acute kidney injury is necessary to prevent morbidity [2].
This paper will review the clinical presentation of acyclovir
(Zovirax) nephrotoxicity and discuss potential mechanisms
for its prevention and treatment.
2.CaseDescription
2.1. History. Mr. A, a 25-year-old male with a past medical
history of bipolar disorder, was seen in an outpatient clinic
3 days prior to admission where he was started on oral
acyclovir 800mg 5 times a day and vicodin for a diagnosis
of Herpes Zoster. He then presented to the emergency
department with a one-day history of pruritis, redness, and
blurry vision of the left eye. In addition, he stated the
vesicular rash that was covering a portion of his right lower
abdominal quadrant and right ﬂank was worsening. The
rash was accompanied by a severe burning pain. Outpatient
medications included abilify, xanax, ambien, propranolol,
and trileptal.
2.2. Physical Exam. Afebrile. Oropharynx: moist. Neck:
supple. Heart: regular without murmurs. Lungs: clear to
auscultation bilaterally. Thorax: unremarkable on admission
but developed mild costovertebral tenderness on Day 3.
Extremities: no edema. Skin: multiple crops of vesicles in
diﬀerent stages on the right lower abdominal quadrant and
right ﬂank consistent with T12 and L1 dermatomes. Initial
exam by ophthalmologist was concerning for a corneal
ulcerationbutsubsequentexaminationrevealedonlycorneal
edema.
2.3. Studies. Admission S-Cr 0.9, Peak S-Cr 5.4 with BUN
31 (Normal Ranges for S-Cr and BUN are 0.6–1.2mg/dL2 Case Reports in Medicine
and 7–18mg/dL). Urinalysis collected after rise in S-Cr was
negative for RBCs, WBCs, granular casts, and eosinophils;
it was also negative for crystals although polarizing light
microscopy was unavailable to adequately look for crystals.
Renal sonogram after S-Cr elevation was normal. HIV
negative.
2.4.HospitalCourse. Thepatientwasadmittedtothegeneral
medicine wards but was started on IV acyclovir for herpes
ophthalmicus by the ophthalmology team while still in the
emergency department. He had not been on IV ﬂuids when
he received the IV dose of acyclovir. Subsequent workup
was negative for herpes ophthalmicus and IV acyclovir was
discontinued; unfortunately, by hospital Day 2, the patient’s
S-Crhadmorethantripledsinceadmission.Crystal-induced
nephropathy was suspected and the patient was started on
aggressive IV ﬂuids. Although euvolemic, furosemide was
added to maintain a urine output of at least 150cc/hr.
Further evaluation for other causes of acute kidney injury
wasunrevealing(seeSection 2.3)includinganegativehistory
for exposure to other nephrotoxic agents (NSAIDS, etc.)
prior to, or during, his hospitalization. After peaking on
hospital Day 3, the patient’s S-Cr began to decline back to
baseline over the following three days. The total amount
of acyclovir given was a one-time dose of 800mg IV and
a total of 13.6 grams by mouth prior to the development
of acute kidney injury. The timing of the acute kidney
injury correlated with the IV dose (see Figure 1 for graphical
representation).
3. Case Overview
The patient in this case rapidly developed acute kidney
injury after receiving about 14 grams of acyclovir, including
one IV dose approximately 24 hours before the serum
creatinine began to climb. He had no other risk factors for
developing acute kidney injury and was not volume depleted
on examination. He was relatively asymptomatic but did
complain of ﬂank pain on days 3–5 of the hospital stay
which has been reported in other cases of acyclovir induced
nephropathy[1].Aftermaintaininghisurineoutputatahigh
rate with IV ﬂuids and furosemide, his renal function began
to improve towards baseline.
4. Discussion
This case describes a patient with no underlying comor-
bidities developing acute kidney injury secondary to crystal
nephropathy after receiving just one IV dose of acyclovir.
Other potential mechanisms of injury include acute inter-
stitial nephritis (AIN) and acute tubular necrosis (ATN);
however, the most commonly described mechanism is
obstructive nephropathy [3]. In this particular case, uri-
nalysis and peripheral blood smear did not support an
ATN or AIN diagnosis. The basis for a diagnosis of crystal-
induced nephropathy in this patient is supported by the
clinical history and time course of the acyclovir adminis-
tration. Urinalysis did not show crystals, although without
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Figure 1: One dose of 800mg of IV acyclovir was given on Day 1
and then the patient received one dose of 800mg orally that night.
On the morning of Day 2, the acute kidney injury was found and
acyclovirwasstoppedimmediately.Thepatienthadreceived800mg
of acyclovir orally ﬁve times a day for three days before hospital
admission (prior to Day 1).
polarizing light microscopy, they would have been diﬃcult
to see. In addition, the patients kidney injury was noticed
immediately and measures were taken to increase urinary
ﬂow rates before the urinalysis could be collected. With
these two factors, it was not surprising to us that crystals
were not seen. There has been some evidence in animal
models that acute kidney injury can occur secondary to
acyclovir administration without crystal obstruction, but
from eﬀects on renal microcirculation, although the exact
mechanism is unknown [3]. Although there is a small
chance of acute kidney injury without crystal obstruction,
there has been suﬃcient evidence to show that kidney
injury secondary to crystal obstruction is the most common
and dominant mechanism and thus the likely diagnosis
in this case [1]. Acyclovir, which is relatively insoluble in
urine, is rapidly ﬁltered by the glomeri and secreted by the
renal tubules which can produce high urine concentrations,
especially in patients with decreased urine ﬂow rates [1].
Oral acyclovir has poor bioavailability and usually only
causes nephropathy when the patient is severely volume
depleted or at high doses in relation to renal function
[1]. IV administration is necessary to achieve high blood
concentrations, which explains why crystal nephropathy is
more common with IV administration. Renal excretion
accounts for 60%–90% of acyclovir elimination [1]. WhenCase Reports in Medicine 3
Table 1: Risks, diagnosis, prevention, and treatment of acyclovir crystal nephropathy.
Risk factors Laboratory and clinical
ﬁndings Prevention Treatment
Hypovolemia Increased Cr, rapid and
usually within 12–48 hours
Establish euvolemia
before medication
administration
If possible, discontinue or
reduce dose
Rapid IV infusion Pyuria Infuse drug slowly (over
1-2 hours)
Establish high urinary ﬂow
with IV ﬂuids and
furosemide (>150cc/hr)
Concurrent acute kidney
injury before medication
administration
Hematuria Adjust dose for renal
function Hemodialysis if necessary
Excess medication
dosage in relation to
renal function
Birefringent
Needle-shaped crystals
Avoid other nephrotoxic
agents
May replace acyclovir with
famciclovir in certain
instances while increasing
urinary ﬂow rate
Concurrent use of other
nephrotoxic agents
Pt. may complain of
associated ﬂank pain
Pt. may be oliguric
IV: intravenous, Cr: Creatinine, cc: milliliters, and hr: hour
intratubular deposition of crystals occurs, the nephron
becomes obstructed leading to increased resistance to renal
blood ﬂow and subsequent elevation of the S-Cr [1, 3].
The importance of monitoring renal function in hospitalized
patients on acyclovir is strongly supported by this case
presentation. The possibility for chronic kidney injury is
a strong concern if the renal insuﬃciency is not rapidly
detected [2]. In addition, there is strong evidence that
acyclovir/valacyclovir can also cause neurotoxicity in the
setting of kidney injury, which could further complicate
the patient’s clinical picture [4]. Common laboratory ﬁnd-
ings other than an increase in S-Cr include hematuria
and pyuria on urinalysis, as well as birefringent needle-
shaped crystals seen on polarizing light microscopy [1]. The
risk of acyclovir induced nephropathy can be minimized
with empiric IV ﬂuids to establish euvolemia before drug
administration, avoiding rapid infusion of the drug (infuse
slowly over 1-2 hours), and adjusting the dose for renal
function if necessary [1]. Other nephrotoxic drugs such as
aminoglycosides and cyclosporine also place the patient at
a higher risk of developing kidney injury with acyclovir
therapy. Treatment of acyclovir nephrotoxicity is supportive
with discontinuation or reduction of the drug in addition
to maintaining a high urinary ﬂow rate (>150cc/hr) with
IV ﬂuids and furosemide [1]. There is limited evidence
that famciclovir may be substituted for acyclovir if renal
toxicity develops for treatment of certain infections [5]. In
patients that develop severe renal failure or do not respond
to treatment, hemodialysis is an option to remove the
oﬀending drug and support renal function [1]. Acyclovir
is commonly used in transplant patients, herpes virus, and
varicella zoster virus infections, and other patients who
present with potential viral CNS infections; hence, clinicians
must be familiar with the potential side eﬀects associated
with its use and how drug-associated complications can be
treated.
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